Colchicine for Reduction of Periprocedural Myocardial Injury in Percutaneous Coronary Intervention

Launched by SOHAG UNIVERSITY · Feb 16, 2023

Keywords

ClinConnect Summary

Prospective open-label randomized cohort study including two groups of patients admitted and prepared for elective PCI at cardiology unit, IMD, Sohag University Hospital, these two groups are:

1. group of patients received oral tablet colchicine 6-24 hours before PCI loading dose 1 mg followed by 500 mcg after one hour.

N.B. usual side effects of colchicine gastrointestinal disorders rarely, myalgia and weakness. Treatment of side effects symptomatic treatment ( antiemetic, etc.)
2. control group of patients. Number of patients according to sample size equation.

Sample size equation i...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Elective PCI in ACS patients with cardiac troponin peaked and stabilized and CCS patients .
• • 2. PP Myocardial Injury (Any increase in post-PCI troponin if pre-PCI troponin is negative or rise in post-PCI troponin above baseline pre-PCI troponin when it is peaked and stabilized).
• • 3. PPMI (rise in post-PCI troponin plus new evidence of ischemia).
• Exclusion Criteria:
• • 1. Patients with active infections.
• • 2. Patients taking anti-inflammatory medications.
• • 3. Patients presented with ACS( still rising troponin).
• • 4. Severe renal impairment ( creatinine clearance \< 45 ml/min ).
• • 5. Primary PCI, rescue PCI, pharmacoinvasive therapy.
• • 6. Connective tissue diseases.